Roche reported that its oral selective estrogen receptor degrader giredestrant met the primary endpoint in a Phase III adjuvant study, extending invasive disease‑free survival versus standard endocrine therapy in ER‑positive, HER2‑negative early breast cancer. The positive interim readout marks the first late‑stage win for an oral SERD in the adjuvant setting and prompted renewed investor interest in competitors developing oral degraders or antagonists. Roche said the trial showed a meaningful disease‑control benefit and a favorable safety profile so far; analysts noted that an approval in the adjuvant setting would broaden SERD use beyond later‑line metastatic disease. The result boosts the class and creates immediate strategic pressure on rivals—particularly firms with late‑stage SERDs or combination strategies. Sources: Roche announcement and clinical commentary.